Thus, deregulated TLR6 expression may potentiate TLR2-mediated liver inflammation in NAFLD pathogenesis, and also serve as a potential peripheral biomarker of obesity-related NASH. Here, TLR6 is linked to metabolic dysfunction-associated steatotic liver disease.